Four Associations Signed Memorandum of Understanding to Promote the Professionalization and Formal Management of Medical Representatives


Tuesday June 28, 2016,  Beijing: the 2016 Pharmaceutical Enterprises Ethical Business Practices China  Forum jointly organized by 17 pharmaceutical industry associations was convened  in Beijing with the agenda to further implement the Pharmaceutical  Enterprise Ethical Business Practice (hereinafter referred to as the “Ethical  Business Practice”), enhance industry self-discipline, and standardize  communication between medical institutions and pharmaceutical enterprises. Vice  Director of SME department of MIIT Xie Pengfei and Vice Chairman of CAEFI Li  Ling attended the forum and delivered speeches.


The Ethical Business  Practice originated from the APEC Codes of Business Ethics for the Biopharmaceutical  Sector, known as the Mexico City Principles, which have been adopted by China’s  pharmaceutical industry for four years now and endorsed by 17 industry Associations  in China. “Further implementation of the Ethical Business Practice is the  responsibility of all APEC economies including China and represents the  consensus of China’s pharmaceutical industry as well”, said Pan Guangcheng, Executive  Chairman of the China Pharmaceutical Industry Association (CPIA).“In the communication  between medical professionals and the pharmaceutical industry, medical  representatives play an important role and the standardization and  formalization of their occupation are undoubtedly the key drivers for the  implementation of the Ethical Business Practice”, said Yao Tongli, Vice Chairman  of the Pharmaceutical Enterprises Promotion Association (CPEP). “Therefore, the  CPIA, the China Association of Traditional Chinese Medicine (CATCM), the CPEP  and the R&D-based Pharmaceutical Association Committee under the China  Association of Enterprise with Foreign Investment (RDPAC) have signed a  memorandum of understanding for the establishment of a joint working group for  the professionalization and formal management of medical representatives.”


The 2015 edition of the  Classification of Occupations in the People’s Republic of China  (“Classification of Occupations”) has included the occupation of medical  representatives, defining them as “professionals engaged in the  transmission, communication and feedback of pharmaceutical information on  behalf of pharmaceutical manufacturers.” This is a milestone in the  occupational development of medical representatives in China and a new starting  point for their professionalization and formalization. Secretary-General of  CATCM Wang Guihua believes that specific work needs to be carried out in many  respects to define the value of medical representatives, including the  establishment of a nationwide occupational evaluation and management system;  training, standardization and evaluation of medical representatives to ensure  their professional knowledge and occupational competence, as well as regular  communication with medical and health industry organizations to explore the  patterns of conduct in the practical work of medical representatives and  promote the sound development of medical institutions and the pharmaceutical  industry. At the forum, four associations have signed the memorandum of  cooperation to adopt the pro-medicine and patient-centered principles,  establish the national occupational management system for medical  representatives, build public consensus on the value of medical  representatives, and promote the sound and orderly development of the pharmaceutical  industry.


411.jpg  4 Associations sign MOU on Cooperation for Promotion and Development of a National Medical Representatives  Occupation Management System

Managing Director of RDPAC Mike Dethick remarked that “the promotion of medical  knowledge and improvement of public health cannot be achieved without the  interactions of the pharmaceutical industry in sharing information. Ethical  integrity of such interactions is not only the key to maintaining the confidence  of various stakeholders for the business operations of the pharmaceutical  industry but the bedrock for the sound operation and global market development  of pharmaceutical enterprises. We are delighted to see that under the  leadership of government, various stakeholders are proactively striving towards  this goal.”


Furthermore, the  representatives of pharmaceutical companies shared their experiences in the  practice of the Ethical Business Practices. 

Related articles: